News

Pembrolizumab plus standard-of-care chemotherapy improved survival in patients with endometrial cancer vs chemotherapy alone.

Bradley McGregor, MD, discusses background of the DAD trial evaluating sacituzumab govitecan-hziy in combination with enfortumab vedotin-ejfv for the treatment of patients with treatment-resistant metastatic urothelial carcinoma.

Encouraging trends were seen with osimertinib and platinum-pemetrexed chemotherapy in patients with EGFR-mutated advanced non–small cell lung cancer in the phase 3 FLAURA2 study.

A biologics license application for subcutaneous amivantamab combined with recombinant human hyaluronidase has been submitted to the FDA for NSCLC indications.

Anthony Conley, MD, discussed findings from a phase 1/2 study investigating the oncolytic virus AdAPT-001 in patients with solid tumors presented at ASCO 2024.

Stephen Williams, MD, MBA, MS, FACS, FACHE, discussed updates from the SunRISe-2 study investigating TAR-200 plus cetrelimab vs chemotherapy in muscle invasive bladder cancer.

Delving into the power of ADCs and intriguing data presented at the 2024 ASCO Annual Meeting, including benefits observed with nivolumab-cabozantinib in advanced RCC and the durable responses seen in endometrial cancer with envafolimab-lenvatinib. We also cover data on JNJ-6420 for metastatic CRPC, and the improvements seen with enfortumab vedotin plus pembrolizumab in urothelial cancer.

Atezolizumab can be given subcutaneously and it is a preferred method of delivery by patients with non–small cell lung cancer, according to results from the phase 2 IMscin002 trial.

Benjamin Lowentritt, MD, discussed findings from real-world analyses looking at enzalutamide or abiraterone vs apalutamide in patients with metastatic castration-sensitive prostate cancer.

The FDA has approved a treatment regimen combining durvalumab with carboplatin and paclitaxel, followed by durvalumab monotherapy, for adults with primary advanced or recurrent endometrial cancer that is deficient in mismatch repair.

MOST study shows high rates of disease progression in low/intermediate-risk myelofibrosis over 4 years, with the rate increasing over time. This offers valuable insight for a patient group with limited prior data.

Tarah Ballinger, MD, discusses what she considers to be the biggest developments from the 2024 ASCO Annual Meeting.

Paolo Ghia, MD, PhD, discusses background of the phase 2 CAPTIVATE trial.

The phase 3 SIERRA study revealed that only Iomab-B recipients achieved the primary end point of durable complete remission.

Jaime Merchan, MD, discusses findings from an analysis presented at the 2024 ASCO Meeting.

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

Amivantamab plus chemotherapy significantly prolonged progression-free survival in patients with EGFR-mutant advanced non–small cell lung cancer.

Finly Zachariah, MD, discusses the rationale behind implementing an AI mortality model at City of Hope, Duarte, California, which enhances the opportunity for patient-clinician discussions on end-of-life preferences, thereby boosting palliative care.

Chakra Chaulagain, MD, discusses findings from a comprehensive examination of National Cancer Database data from 2004 to 2020 regarding the utilization of autologous hematopoietic stem cell transplantation in patients with multiple myeloma.

The FDA granted approval to repotrectinib for the treatment of metastatic or locally advanced solid tumors with an NTRK gene fusion.

In an interview with Targeted Oncology, Sarah Sammons, MD, discussed an analysis of the DESTINY-Breast03 trial, highlighting the need for further research on trastuzumab deruxtecan in other breast cancer subtypes and solid tumors with brain metastases.

Francis P. Worden, MD, provides a brief overview of the approval of selpercatinib and what it means for patients with RET fusion-positive thyroid cancer.

Findings from a phase 1 trial presented at ASCO showed that axicabtagene ciloleucel was safe with clinical activity seen among patients with relapsed/refractory primary and secondary central nervous system lymphoma.

Patients with chronic myeloid leukemia can have a near-normal life expectation when treated with BCR::ABL1 tyrosine kinase inhibitors.

Anita Boyapati, PhD, discussed her research on the link between soluble BCMA and both disease burden and response to BCMA-targeted therapies in this patient population.

mKRAS-specific T-cell responses that were produced by ELI-002 7P correlated with tumor biomarker responses among patients with pancreatic and colorectal cancer.

A self-taught AI tool that accurately diagnoses adenocarcinoma and predicts cancer recurrence has been developed and has shown to outperform traditional methods.